





2025 4 FDA

AI

NAMs

NAMs

NAMs

AI

NAMs

NAMs

AI
(*in vitro*)

(*ex vivo*)

(*in silico*)



3D

Organ-on-Chip

MPS

Organoid



PBPK

QSP

QST


/



NAMs

NAMs





NAMs



AI

Target-to-hit Hit-to-lead Lead-to-PCC








CDE 2020

CRA

IND










ABT-263 24 CTG ADP 5 anti-CD42 anti-CD62P
 ABT-263 ADP
 CD62P+ cells



HepG2 mRNA siRNA 10 nM siRNA




Smarca2/4 PROTAC MV-4-11 (DMSO, 10 nM, 100 nM), A B PROTAC 10nM
 Smarca2 Smarca4 100nM






PDXO HER2 : &



-
-
-



.....

